AUSTIN, Texas–Luminex Corporation (NASDAQ: LMNX), the worldwide leader in multiplexed solutions, announced today that it has performed computer-based sequence analysis of the U.S. swine flu patient isolates and compared them to the primer sequences of the Company’s xTAG RVP assay. In the interest of providing information to its customers and to public health labs, Luminex is reporting these interim computer-based results and will provide further updates once actual patient samples have been tested with the RVP assay.

xTAG RVP is the only commercially available FDA-cleared test that can distinguish different subtypes of the flu virus. A computer-based analysis of the swine flu sequences compared to the primers in the xTAG RVP product indicate that a swine flu positive patient sample is likely to be correctly identified by the portion of the RVP assay which detects the flu A matrix gene. However, the H1 subtyping portion of the RVP assay is not predicted to identify the swine flu H1 gene, even though the Atlanta Center for Disease Control and Prevention (CDC) has identified the swine flu strain as an H1 subtype strain. The reason for this finding is that the new swine flu strain is significantly different from normal, seasonal H1 subtype flu A.

Luminex is working with its customers and other public health labs to identify patient samples to empirically confirm these computer-based sequence analysis results. Luminex will provide further information once these results are complete.

“If our prediction based on sequence analysis is confirmed, RVP should prove to be very useful for swine flu surveillance programs,” said Patrick Balthrop, chief executive officer of Luminex. “A test which can identify the virus, but which provides a different result from that seen with a normal, seasonal H1 flu A sample, is the type of test required for effective surveillance programs. Our preliminary results suggest that xTAG RVP could provide that type of result. We are working hard to verify this sequence-based analysis with real patient samples and will provide further updates as soon as possible.”

The Luminex xTAG RVP was developed by Luminex Molecular Diagnostics and was cleared by the FDA in January of 2008. Luminex’s unique multiplexing xMAP® Technology is the key to delivering the capability to determine subtypes from one sample, enabling the RVP assay to simultaneously detect 12 respiratory viruses and subtypes at the DNA/RNA level in a matter of hours. The package insert for xTAG RVP instructs the user how to proceed in case of encountering an “unsubtypeable” flu A sample. These instructions include contacting a public health lab to conduct follow-up analysis of the sample to identify if the patient is infected with a flu A strain which could pose a pandemic threat, such as swine flu.

About Luminex Corporation

Luminex Corporation develops, manufactures and markets proprietary biological testing technologies with applications throughout the diagnostic and life sciences industries. The Company’s xMAP® multiplex solutions include an open-architecture, multi-analyte technology platform that delivers fast, accurate and cost-effective bioassay results to markets as diverse as pharmaceutical drug discovery, clinical diagnostics and biomedical research, including the genomics and proteomics research markets. The Company’s xMAP technology is sold worldwide and is already in use in leading clinical laboratories as well as major pharmaceutical, diagnostic and biotechnology companies. Further information on Luminex Corporation or xMAP technology can be obtained at www.luminexcorp.com.

Statements made in this release that express Luminex’s or management’s intentions, plans, beliefs, expectations or predictions of future events are forward-looking statements. The words “believe,” “expect,” “intend,” “estimate,” “anticipate,” “will,” “could,” “should” and similar expressions are intended to further identify such forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. It is important to note that the Company’s actual results or performance could differ materially from those anticipated or projected in such forward-looking statements. Factors that could cause Luminex’s actual results or performance to differ materially include risks and uncertainties relating to, among others, market demand and acceptance of Luminex’s products, the Company’s dependence on strategic partners for development, commercialization and distribution of products, concentration of the Company’s revenue in a limited number of strategic partners, fluctuations in quarterly results due to a lengthy and unpredictable sales cycle and bulk purchases of consumables, Luminex’s ability to scale manufacturing operations and manage operating expenses, gross margins and inventory levels, potential shortages of components, competition, the timing of regulatory approvals, the implementation, including any modification, of the Company’s strategic operating plans, risks and uncertainties associated with implementing our acquisition strategy and the ability to integrate acquired companies or selected assets into our consolidated business operations, as well as the risks discussed under the heading “Risk Factors” in Luminex’s Reports on Forms 10-K and 10-Q, as filed with the Securities and Exchange Commission. The forward-looking statements contained herein represent the judgment of Luminex as of the date of this press release, and Luminex expressly disclaims any intent, obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in Luminex’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.